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Abstract
Background: Oestrogen receptor beta (ERβ) modulates ERα activity; wild type ERβ (ERβ1) and its splice
variants may therefore impact on hormone responsiveness of breast cancer. ERβ2/ERβcx acts as a dominant
negative inhibitor of ERα and expression of ERβ2 mRNA has been proposed as a candidate marker for outcome
in primary breast cancer following adjuvant endocrine therapy. We therefore now assess ERβ2 protein by
immunostaining and mRNA by quantitative RT-PCR in relation to treatment outcome.
Methods: ERβ2-specific immunostaining was quantified in 141 primary breast cancer cases receiving adjuvant
endocrine therapy, but no neoadjuvant therapy or adjuvant chemotherapy. The expression of mRNA for ERβ2/
ERβcx was measured in 100 cases by quantitative RT-PCR. Statistical analysis of breast cancer relapse and breast
cancer survival was performed using Kaplan Meier log-rank tests and Cox's univariate and multivariate survival
analysis.
Results: High ERβ2 immunostaining (Allred score >5) and high ERβ2 mRNA levels were independently
associated with significantly better outcome across the whole cohort, including both ERα positive and negative
cases (Log-Rank P < 0.05). However, only ERβ2 mRNA levels were significantly associated with better outcome
in the ERα + subgroup (Log-Rank P = 0.01) and this was independent of grade, size, nodal status and progesterone
receptor status (Cox hazard ratio 0.31 P = 0.02 for relapse; 0.17 P = 0.01 for survival). High ERβ2 mRNA was
also associated with better outcome in node negative cases (Log Rank P < 0.001).
ERβ2 protein levels were greater in ERα positive cases (T-test P = 0.00001), possibly explaining the association
with better outcome. Levels of ERβ2 protein did not correlate ERβ2 mRNA levels, but 34% of cases had both
high mRNA and protein and had a significantly better outcome (Log-Rank relapse P < 0.005).
Conclusion: High ERβ2 protein levels were associated with ERα expression. Although most cases with high
ERβ2 mRNA had strong ERβ2 immunostaining, mRNA levels but not protein levels were independently predictive
of outcome in tamoxifen-treated ERα + tumours. Post-transcriptional control needs to be considered when
assessing the biological or clinical importance of ERβ proteins.
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Oestrogen Receptor alpha (ERα) is an accepted prognostic
marker in breast cancer and is used to plan adjuvant endo-
crine treatment (e.g. use of the anti-oestrogen tamoxifen).
The majority of the breast cancers are positive for ERα
(ERα+), but not all patients with ERα+ cancer respond to
endocrine therapy and many subsequently succumb to
local relapse or metastasis. The failure of some breast can-
cers to respond to tamoxifen, currently the most common
adjuvant endocrine treatment, is a major clinical problem
and several resistance mechanisms have been elucidated
[1,2].
ERβ and its splice variants are differentially expressed in a
variety of normal tissues and cancers including breast
[3,4], but not all published studies are in agreement about
the role of ERβ isoforms in breast cancer [4-13]. The
ERβ2/ERβcx variant arises from alternative splicing of the
last ERβ exon. This produces a truncated ERβ protein una-
ble to bind oestradiol as a result of a disorientated helix12
in the ligand binding domain [14,15]. ERβ2 acts as a
dominant negative modulator of ERα [14,16] and there-
fore might be expected to have a protective effect in breast
tumorigenesis or outcome, at least for ERα + breast cancer.
Further verification of ERβ variants, including ERβ2, as
potential clinical markers is still required. Many previous
studies make use of mRNA levels as a surrogate marker for
ERβ protein expression and few have attempted to relate
mRNA to protein levels. Other studies that do assess the
expression of ERβ protein use techniques that rely on
detection of N-terminal epitopes that are shared by most
variants. A good proportion of studies also fail to take into
account menopausal status, stage of the disease or the
treatment given.
We have previously identified ERβ2 mRNA levels as being
more closely associated with treatment outcome than
mRNA levels of ERβ1 or ERβ5 [17] in a treatment-specific
cohort of postmenopausal women receiving adjuvant
endocrine treatment but not chemotherapy. However in
the same setting, mRNA levels for the wild-type ERβ1 iso-
form do not correlate well with protein levels [9]. With the
aim of clarifying the significance of ERβ2 expression in
tamoxifen response and investigating the relationship
between ERβ2 mRNA and protein levels, we have there-
fore set out to evaluate both expression of ERβ2 protein by
immunostaining and expression of ERβ2 mRNA by quan-
titative RTPCR (qRTPCR). Our hypothesis was that ERβ2
may be associated with outcome following adjuvant
tamoxifen treatment of breast cancers and therefore be
useful as a predictive marker or give some insight into
mechanisms of resistance.
We were able to confirm a significant association of both
high ERβ2 protein and high mRNA levels with good out-
come, but ERβ2 protein levels were not a useful marker of
outcome. Strong ERβ2 staining was associated with better
outcome, but not independently of ERα. Although ERβ2
mRNA and protein levels did not correlate with each
other, approximately one third of cases (34%) were seen
to have both high mRNA and high protein levels; these
had a significantly better outcome than the other cases, so
ERβ2 protein may have a role in improved outcome for a
subset of breast cancers.
Methods
Patients and specimens
Patients undergoing treatment for invasive breast cancer
during the period 1993 and 1999 at the Royal Liverpool
University Hospital were identified from a database at the
Cancer Tissue Bank Research Centre (CTBRC), University
of Liverpool [9]. A total of 141 postmenopausal patients
(Table 1) with primary breast cancer were selected,
median age was 68 years (range 47–87). They had been
treated by surgery (47 mastectomy, 94 wide local exci-
sion) and radiotherapy (70 cases), but had not received
systemic chemotherapy or primary endocrine therapy. All
patients received adjuvant endocrine therapy; either
tamoxifen (n = 133) or as part of the ATAC trial (n = 8).
Clinical and histological characteristics are summarized
in Table 1. ERα and progesterone receptor (PgR) status
was obtained from review of histopathology notes or
determined immunohistochemically using a cut-off of
10% positive cells [9]. Ki67 immunostaining was reported
previously as % positive tumour cells [9]. Clinical follow-
up data was recorded by retrospective case-note review
with data from surviving patients censored at the date last
seen. Outcome measures were breast cancer relapse (BCR)
and breast cancer survival (BCS). Median follow-up was
71 months for BCR (range 9 to 113) and 79 months for
BCS (range 11 to 113). Ethical approval for the study was
obtained from The Liverpool Adult Research Ethics Com-
mittee (Reference 01/116), who also approved the collec-
tion of samples by the CTBRC with informed consent.
Based on estimates of proportions of ERβ2 positive cases
from our previous study [17] and available outcome data,
we determined that this study would have 80% power
with an α value of 0.05 to detect a hazard ratio below 0.73
or above 1.40 in the whole cohort (below 0.63 or above
1.74 in the ERα + cohort), which we considered appropri-
ate to give an indication of clinical utility.
Immunohistochemistry
Histological sections (4 µm) were cut from the formalin-
fixed, paraffin-embedded specimens, placed onto 3-ami-
nopropyltriethoxysilane-coated slides and endogenous
peroxidase activity was blocked using 3% (v/v) hydrogenPage 2 of 9
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microwaving for 10 minutes in antigen unmasking solu-
tion (H3300, Vector Laboratories Ltd., Peterborough,
UK). Slides were pre-incubated in Protein Block Serum-
Free (DakoCytomation, Ely, UK) for 10 minutes. Immu-
nostaining for ERβ2 was performed overnight at 4°C with
mouse anti-human ERβ2 monoclonal antibody
MCA2279S (clone no 57/3, Serotec; raised to the unique
C-terminal region [18] and previously used for breast
tumour staining [4]), diluted 1 in 25 in 0.1% (w/v) BSA,
50 mM Tris, 15 mM NaCl, pH7.6. The bound antibodies
were detected using the DAKO LSAB2 system, according
to manufacturer's recommendations (DakoCytomation).
The bound antibodies were visualized as a brown stain by
incubating with DAB chromogen (Sigma-Aldrich, Gilling-
ham, UK). Sections were counterstained with Mayers'
Haemotaxylin (Sigma-Aldrich) and mounted in DPX
(Merck, Dorset, UK). In controls the ERβ2 antibody was
preincubated with a molar excess of immunising synthetic
peptide (CMKMETLLPEATMEQ [18]) prior to application
to sections from positively-staining specimens. Nuclear
staining was abolished in these blocked controls, but
some cytoplasmic staining remained. Scoring of tumour
sections was performed for nuclear staining only. Stained
slides were analysed independently by two observers (RV
and VA) using light microscopy; the percentage of posi-
tively stained malignant cells was estimated (%+) as was
the staining intensity, an immuno-score (Allred) was cal-
culated according to the Allred system [19].
qRTPCR
RNA of suitable quality for 100 cases was obtained from
the CTBRC; testis RNA (Promega, Southhampton, UK)
and MCF7 cell line RNA were used as positive controls.
Cases were selected for RNA analysis following independ-
ent histological review of adjacent sections, so as to avoid
high levels of tissue heterogeneity. Samples from all cases
consisted of at least 75% tumour cells and 67% of cases
had at least 90% tumour cells. Inflammatory infiltrates
were present in a minority of cases (at 10% in 15 cases and
at 25% in 4 cases).
Reverse transcription was performed in duplicate as
described previously with oligo-dT primers [17], but using
1.5 µg total RNA and Superscript III reverse transcriptase
(Invitrogen, Paisley, UK). Quantitative PCR for ERβ2 was
performed on a Bio-Rad Icycler Real-Time PCR machine
(Bio-Rad Laboratories Ltd., Hertfordshire, U.K.) using 4
µ1 of a 1/2 dilution of cDNA per reaction (equivalent to
cDNA from approximately 150 ng of total RNA). ERβ2
PCR reactions included 1× IQ Supermix (Bio-Rad) and
PCR primers and a Taqman probe (as given in Table 2).
For control gene PCR (HPRT, GAPDH) and ERα 4 µl of a
1/50 dilution was used and the reaction contained IQ
SYBR Green Supermix (Bio-Rad). The PCR reactions con-
sisted of a hot-start Taq Polymerase activation step of
95°C for 3 minutes, followed by conditions shown to be
produce unique, specific bands for each mRNA (Table 2).
Expression levels of mRNA for each gene were calculated
using standard curves produced with the relevant cloned
cDNAs and correcting for the control genes (HPRT and
GAPDH). All amplicons crossed introns to avoid amplifi-
cation of genomic DNA and the identity of PCR products
was confirmed by agarose gel electrophoresis and DNA
sequence analysis, as described previously [17].
Statistical analysis
Power calculations were performed using the PS program
[20] with survival analysis implementation of Schoenfeld
and Richter [21]. All other statistical analyses were per-
formed using the SPSS package (Windows, v.11). The
degree of agreement for immunostaining between observ-
ers was assessed using the Kappa statistic. Pearson correla-
tion and Spearman's rank correlation were used as
Table 1: Patient characteristics
Characteristic Immunostaining 
cohort n (total = 141)
qRTPCR cohort n 
(total = 100)
Histology






























1 data from O'Neill et al. [9]
2 based on ROC-derived cut-pointsPage 3 of 9
(page number not for citation purposes)
BMC Cancer 2007, 7:131 http://www.biomedcentral.com/1471-2407/7/131measures of association. Student's T-test and the Mann-
Whitney U test (MW) were used to compare between
groups of cases defined by other variables; for paired data
paired T-tests and Wilcoxon signed ranks tests were used.
Optimal cut-points for continuous variables were deter-
mined using Receiver Operating Characteristic (ROC)
plots for BCR and BCS at 5 years after surgery. Curves for
outcome were generated using the Kaplan-Meier method
for censored data, with surviving patients' data being cen-
sored at the date of their last clinic visit, and were com-
pared using the Log Rank test. Unadjusted hazard ratios
(HR) ± 95% confidence intervals (CI) were obtained
using Cox's univariate analysis. Cox's regression model
was used for multivariate survival analysis. For outcome
analysis grade was dichotomised as grade 3 vs. other
grades, size was dichotomised as T1 vs. other sizes.
Results and Discussion
Previous assessments of the role of ERβ2 in breast cancer
treatment outcome have been limited, with most clinical
studies being performed in broader groups of patients and
focussing on other associations, largely related to pathol-
ogy. Our own previous data [17] was based on a semi-
quantitative RTPCR analysis using an assay in which ERβ5
is co-amplified with ERβ2 and distinguished based on size
of the PCR product, similar to the triple-primer assay used
elsewhere [22,23]. We found that, using the arbitrary cut-
off imposed by detection sensitivity, ERβ2 mRNA expres-
sion was more closely associated with survival benefit
than ERβ1 or ERβ5 mRNA expression. We therefore set
out to establish whether ERβ2 protein levels similarly pre-
dicted patient outcome. We defined discriminatory cut-
points of ERβ2 levels in a non-arbitrary manner, using
ROC analysis, and used these to assess the relationship
between ERβ2 expression and outcome.
Immunohistochemical staining for ERβ2
A cohort of 141 cases were stained by immunohistochem-
istry for ERβ2 (Table 1) including 98 ERα + cases. ERβ2
staining was assessed by 2 observers (R.V., V.A.) using the
Allred scoring system and also as percentage positive cells
(%+), with good agreement between observers (Allred
Spearman 0.91 P = 1.0 × 106, %+ Pearson 0.92 P = 3.4 ×
1059). At the cut-point used for outcome analysis the
Kappa score was 0.87. A consensus score was produced
and used herein, representative examples of immunos-
taining are shown in Figure 1. The frequencies of each
score were: score 0, 2 cases (1.4%); 3, 3 cases (2.1%); 4, 9
Immunohistochemical staining for ERβ2Figure 1
Immunohistochemical staining for ERβ2. Breast carci-
nomas showing different levels of staining; examples of Allred 
score 0 (A), 3 (B), 4 (C), 5 (D), 6 (E), 7 (F) and 8 (G). H-K are 
low (H, J) and high (I, K) magnification images of the same 
tumour stained normally (H, I) and following blocking with 
synthetic peptide (J, K).
Table 2: qPCR conditions
Gene Primers/Probes3 Conc. (µM) Amplicon Cycling conditions
ERβ21 For-ATCCATGCGCCTGCTAAC 0.5 bases 1265–1343 50 cycles:
Rev-GAGTGTTTGAGAGGCCTTTTCTG 0.5 GenBank: AF124790 95°C 20s, 52°C 20s
Probe-TCCTGATGCTCCTGTCCCACGTCA 0.2
ERα2 For-CCACCAACCAGTGCACCATT 1.0 bases 1030–1137 40 cycles: 95°C 20s
Rev-GGTCTTTTCGTATCCCACCTTTC 1.0 GenBank: NM_000125 60°C 20s, 72°C 30s
HPRT2 For-GTGTTGGATATAAGCCAGACTTTGTT 1.0 bases 597–763 40 cycles:
Rev-AACTCAACTTGAACTCTCATCTTAGGC 1.0 GenBank: NM_000194 94°C 30s, 64°C 60s
GAPDH2 For-GCATCCTGGGCTACACTGAG 0.5 bases 917–1079 40 cycles:
Rev-TCCACCACCCTGTTGCTGTA 0.5 GenBank: NM_002046 94°C 30s, 65°C 90s
1 primers from Critchley et al. [25];
2 primers designed in-house.
3 For = forward primer; Rev = reverse primer; Probe = Taqman probe.Page 4 of 9
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61 cases (43.3%).
ERβ2 immunostaining significantly correlated with that
for ERα (%+ Pearson 0.42 P = 7.8 × 107, Allred Spearman
0.40 P = 4.1 × 106) and to a lesser extent PgR (%+ Pearson
0.18 P = 0.035). ERβ2 immunostaining was greater in ERα
+ cases (mean %+ = 69) than in ERα- cases (mean %+ =
52; P = 0.00001 T-test) and ERβ2 Allred score was greater
in PgR+ cases than PgR- cases (P = 0.033 MW). The per-
centage of ERβ2 positive cells were somewhat lower in
grade 3 cases (P = 0.042 MW), in keeping with the associ-
ation with ERα status. There was no association with Ki67
staining, vascular invasion, nodal status, age or size, or
with ERβ1-specific immunostaining [9]; most previous
studies have similarly failed to show clear links to many
clinical and pathological parameters.
The association seen here between ERβ2 and ERα has not
always been seen by others. Although case selection and
clinical setting may have some bearing on this, it is also
possible that such correlations are due to better tissue
preservation of antigens in some blocks of tissue. We do
not think that this is the case here, as in the same cohort
ERα but not ERβ2 inversely correlated with p53 immu-
nostaining (unpublished data) and ERα did not correlate
with ERβ1 [9]. If antigen preservation was a major influ-
ence on immunostaining patterns it is unlikely that such
complex inter-relationships would be evident.
Association of ERβ2 protein with patient survival
Using the Allred scoring system, tumours were designated
as either ERβ2 low (score 5 or lower, n = 39) or ERβ2 high
(score 6 or higher, n = 97, 71%). ERβ2 status significantly
associated with ERα status (P = 0.001 Chi square) and
within the subgroup of ERα positive women who received
adjuvant tamoxifen there were 18 ERβ2 low cases and 67
ERβ2 high cases (79%).
Within the group as a whole (ERα + and ERα- cases), high
ERβ2 protein levels were significantly related to a better
relapse free survival (BCR P = 0.049 Log Rank, Figure 2),
but not breast cancer survival (BCS P = 0.16, Figure 3).
However, in both cases the survival curves converge at
later time-points; with shorter follow-up time a stronger
relationship with outcome was seen (5-year BCR P =
0.018 Log Rank, HR 0.50 CI 0.27–0.90 P = 0.020; 7 year
BCS P = 0.048 Log Rank, HR 0.50 CI 0.27–0.90 P =
0.020).
When ERα status and ERβ2 immunoscore were included
as the only two variables in multivariate analysis of 5 year
BCR, ERα status was independently significant (HR 0.38
CI 0.22–0.66 P = 0.001) whereas ERβ2 did not retain
independent significance (HR 0.76 CI 0.43–1.33 P =
Kaplan Meier plots for breast cancer relapseFigure 2
Kaplan Meier plots for breast cancer relapse. Plots are 
shown for dichotomised levels of ERβ2 immunostaining in 
the whole cohort (A, 34 events in 97 ERβ2 high cases and 21 
events in 40 ERβ2 low cases) and dichotomised levels of 
ERβ2 mRNA in the ERα + tamoxifen-treated cohort and (B, 
7 events in 32 ERβ2 high cases and 14 events in 30 ERβ2 low 
cases). Unbroken green lines represent cases with high levels 
of ERβ2, dotted blue lines represent cases with low levels. In 
C cases from the whole cohort were classed as: high for 
both protein and mRNA (unbroken green line, 7 events in 32 
cases); high for protein, low for mRNA (unbroken grey line, 
19 events in 44 cases); low for protein, high for mRNA (dot-
ted unbroken black line, 7 events in 14 cases); or low for 
both protein and mRNA (dotted blue line, 5 events in 7 
cases). In all cases crosses represent censored data and P val-
ues are given for Log Rank tests.Page 5 of 9
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nodal status were included in this multivariate analysis,
only nodal status (HR 3.1 CI 1.5–6.2 P = 0.001) and grade
(HR 1.5 CI 1.1–2.2 P = 0.026) were independently signif-
icant. When considering only ERα +, tamoxifen-treated
cases there was no relationship between ERβ2 immunos-
taining at outcome (BCR P = 0.95, BCS P = 0.65 Log
Rank).
One previous study of only 50 ERα positive cases using
immunostaining with a different antibody raised to the
same ERβ2-specific epitope [7] similarly failed to show
any predictive association with adjuvant tamoxifen treat-
ment. However this analysis was based on detecting dif-
ferences in staining between "sensitive" and "resistant"
cases using the crude measure of relapse within 5 years of
tamoxifen therapy. Unpublished observations [12] also
failed to show any predictive value in an adjuvant setting
and a similar lack of association between ERβ2 immunos-
taining and outcome has recently been demonstrated in
the neoadjuvant setting [4]. Hence the early outcome ben-
efit seen with strong ERβ2 immunostaining was not iden-
tified previously. However, an association of ERβ2 protein
with a favourable outcome has been seen in a metastatic
and locally advanced setting [10]. In this case, not only
was the clinical setting different, but ERβ2 was assessed by
western blot. Therefore the present study is the largest to
date to assess immunostaining of ERβ2 as a predictive
marker of outcome in the postmenopausal, adjuvant
endocrine setting. Results indicate that ERβ2 protein lev-
els did not apparently relate closely to outcome for ERα +
cases. Rather there was some association of ERβ2 immu-
nostaining with better outcome in broader cohorts of
patients (including ERα- cases), due in part to a correla-
tion between ERα and ERβ2 protein levels.
Association of ERβ2 mRNA with patient survival
ERβ2 immunostaining results are at odds with previous
semi-quantitative RTPCR results. We therefore performed
a repeat RTPCR analysis on a larger series of patients, but
with fully quantitative RTPCR using independent cDNA
synthesis reactions and different splice variant specific
PCR conditions. A subgroup of 100 cases (Table 1) with
suitable quality mRNA available were used in qRTPCR for
ERβ2, ERα and control genes HPRT and GAPDH. Expres-
sion of ERβ2 mRNA (mean 0.006 attomoles per µg total
RNA) was significantly lower (P < 106 paired T-test) than
that of ERα (mean 25 attomoles per µg total RNA). These
low levels of ERβ mRNA (also seen with ERβ1 and ERβ5,
results not shown) may contribute to technical difficulties
in reproducibly measuring ERβ variants and hence to the
lack of consistency between different studies.
In the 100 case (ERα + and ERα -) qRTPCR cohort (Table
1), high grade (BCR & BCS P ≤ 0.001), positive nodal sta-
tus (BCR & BCS P ≤ 0.0005), larger size (BCS P = 0.042),
ERα negative status (BCR P = 0.009, BCS P = 0.041) and
PgR negative status (BCR P = 0.032, BCS P = 0.026) were
all associated with poor outcome (Log Rank). Using an
ROC-derived optimal cut-point (0.0040 attomoles per µg
total RNA) for this 100 case cohort in Kaplan Meier Log
Rank analysis, there was a significant association between
higher ERβ2 mRNA expression and good outcome (BCR P
= 0.046 Log Rank, HR 0.51 CI 0.26–1.00 P = 0.0496). As
with ERβ2 immunoscore, this association was stronger at
5 years (5-year BCR P = 0.016 Log Rank, HR 0.39 CI 0.18–
0.87 P = 0.020). Notably, unlike ERβ2 immunostaining,
Kaplan Meier plots for breast cancer survivalFigure 3
Kaplan Meier plots for breast cancer survival. Plots are 
shown for dichotomised levels of ERβ2 immunostaining in 
the whole cohort (A, 27 events in 91 ERβ2 high cases and 17 
events in 38 ERβ2 low cases) and dichotomised levels of 
ERβ2 mRNA in the ERα + tamoxifen-treated cohort and (B, 
4 events in 29 ERβ2 high cases and 12 events in 29 ERβ2 low 
cases). Unbroken green lines represent cases with high levels 
of ERβ2, dotted blue lines represent cases with low levels. In 
all cases crosses represent censored data and P values are 
given for Log Rank tests.Page 6 of 9
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mRNA and ERα immunostaining. Also unlike ERβ2 pro-
tein, ERβ2 mRNA and ERα status were independently
associated with BCR at 5 years (ERβ2 HR 0.43 CI 0.20–
0.95 P = 0.036, ERα HR 0.36 CI 0.18–0.75 P = 0.006).
These two measures of ERβ2 expression therefore seem to
behave differently in relation to ERα status and treatment
outcome.
Further outcome analysis was limited to ERα positive
women who received adjuvant tamoxifen and had a
defined breast cancer related outcome (n = 62 BCR, n = 58
BCS). High grade (BCR P = 0.006, BCS P = 0.0008) and
positive nodal status (BCR P = 0.003, BCS P = 0.007)
maintained their association with worse outcome (Log
Rank). ROC plots for BCR and BCS at 5 years indicated a
significant relationship between good outcome and high
qRTPCR values for ERβ2 (BCR area under curve 0.68 CI
0.52–0.84, P = 0.036) and the optimal cut-point was
0.0039 attomoles per µg total RNA. There were significant
associations between outcome and ERβ2 mRNA level
using the ROC-derived cut-point (Figures 2 and 3). High
ERβ2 mRNA was significantly associated with better out-
come (BCR P = 0.0095 Log Rank, HR 0.32 CI 0.13–0.79;
BCS P = 0.011 Log Rank, HR 0.25 CI 0.08–0.79). The 5-
year cumulative relapse-free population was 81% in the
ERβ2-high group (standard error 8%), compared to 55%
in the ERβ2-low group (standard error 10%); the 5-year
cumulative BCS was 89% in the ERβ2-high group (stand-
ard error 6%), compared to 62% in the ERβ2-low group
(standard error 10%).
In Cox multivariate analysis of the ERα + tamoxifen-
treated cohort including grade, size, nodal status and PgR
status, high ERβ2 mRNA had independent significance for
good outcome: for BCR ERβ2 (HR 0.31 CI 0.11–0.86, P =
0.024) and nodal status (HR 3.7 CI 1.2–11.5, P = 0.022)
were independently significant; for BCS ERβ2 (HR 0.17 CI
0.05–0.65, P = 0.0095) and grade (HR 1.8 CI 1.03–3.3, P
= 0.041) were independently significant. Notably there
was no significant association between ERβ2 and grade,
size, nodal status or PgR status in this treatment-specific
cohort (all P > 0.35 Chi-square). In ERα +, node negative
cases (n = 33), using a lower cut-off (0.00185 attomoles
per µg total RNA), ERβ2 was significantly associated with
better outcome (BCR P = 0.0005, BCS P < 0.00005 Log
Rank); the 5 year cumulative relapse-free population was
96% in the ERβ2-high group (standard error 4%), com-
pared to 39% in the ERβ2-low group (standard error
24%).
Our results indicate that ERβ2 isoform mRNAs may be an
independent marker for ERα + cases that respond well to
adjuvant tamoxifen treatment. In node negative cases,
where the need for additional markers of response is
greatest, our study shows that low ERβ2 mRNA levels are
significantly related to worse outcome; as the cases in this
subgroup analysis was small, a larger study of node nega-
tive patients is warranted. The fully quantitative nature of
the qRTPCR results allows comparison of mRNA levels
between different ER isoforms and of variant levels
between tumours, but necessitated selection of optimal
cut-points (in this case using ROC analysis) for the dichot-
omization required for standard outcome analysis. It
should be noted that, whilst such dichotomization is use-
ful in demonstrating associations with outcome, true util-
ity of ERβ variant mRNA measurement will only be
demonstrated with larger patient cohorts and may be bet-
ter achieved by treating mRNA quantitation as a continu-
ous variable, as in other RTPCR based outcome predictors
[24].
Association of staining for ERβ2 protein with mRNA 
expression
Associations between high levels of ERβ2 protein (immu-
noscore) or mRNA (qRTPCR) and improved outcome
have been seen, but only the qRTPCR results are signifi-
cant in the clinically relevant ERα + cohort. It is therefore
important to establish the relationship between mRNA
and protein levels in clinical samples. Notably, most pre-
vious RTPCR-based analyses have failed to take into
account the possible translational control when assigning
biological or clinical relevance to ERβ isoform expression.
When assessing the relationship between immunostain-
ing and qRTPCR for paired samples from each case, no
correlation was seen between levels of protein and mRNA
for ERβ2 [Pearson (%+) -0.12 P = 0.24; and Spearman
(Allred) -0.08 P = 0.40]. This is in contrast to ERα in the
same cohort [Pearson (%+) 0.30 P = 0.003; Spearman
(Allred) 0.50 P = 1.0 × 10-6], but a similar lack of correla-
tion was seen previously for ERβ1 [9]. Due to tissue heter-
ogeneity, any mRNA analysis of tissue homogenates
without selection can contribute to discordance with
immunostaining results that are scored on specific cell
types. In order to minimise the impact of such artefacts,
we selected cases for mRNA analysis that had high propor-
tions of tumour cells (see Methods). It is known that lym-
phocytes express ERβ2 mRNA, but when 14 cases with
inflammatory infiltrates were excluded there was still no
significant correlation between ERβ2 mRNA and protein
expression. A major factor in the discordance is that many
cases express high levels of protein, but low mRNA levels;
a situation that is not likely to arise from expression of
mRNA in non-tumour cells. It is however possible that
heterogeneity of expression in the different parts of the
tumour specimen used for mRNA and protein analysis
contributes to the lack of correlation and in situ analysis of
mRNA and protein in adjacent sections might address
this.Page 7 of 9
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when entered into a Cox multivariate model, were inde-
pendently associated with better relapse-free survival in
the whole cohort (ERβ2 protein HR 0.40 CI 0.20–0.80 P
= 0.010, ERβ2 mRNA HR 0.43 CI 0.22–0.83 P = 0.013). In
multivariate analysis of mRNA and protein in the ERα +
tamoxifen-treated cohort, only high ERβ2 mRNA levels
were significantly associated with lower BCR (HR 0.28 CI
0.212–0.72 P = 0.008), but a trend remained for protein
(HR 0.42 CI 0.15–1.19 P = 0.10). Similar results were
obtained for analysis of BCS. This indicates that both
mRNA and protein levels may contribute to the relation-
ship of ERβ2 with improved outcome.
Using the cut-points optimised for outcome analysis, the
majority of cases (69%) with high ERβ2 mRNA levels also
had high levels of ERβ2 protein. However, only a minority
of cases (44%) with high ERβ2 protein were also classified
as having high ERβ2 mRNA. Thus ERβ2 mRNA expression
is frequently associated with expression of significant lev-
els of ERβ2 protein, but ERβ2 protein expression is often
dissociated from mRNA expression. Hence, there is a sub-
set of cases (34%) with concomitant high ERβ2 mRNA
and protein and another subset of cases (44%) in which
high protein levels are not accompanied by high mRNA
levels. The cases with both high ERβ2 protein and mRNA
had a significantly better outcome than those with low
levels of either mRNA or protein or both (P = 0.011 Log
Rank, Figure 2). When cases with high ERβ2 protein and
RNA were compared a group consisting of all other cases
they had significantly better outcome: in the whole cohort
of ERα + and ERα- cases, (BCR P = 0.002 Log Rank, HR
0.67 CI 0.51–0.88 P = 0.004; BCS P = 0.003 Log Rank, HR
0.61 CI 0.43–0.87 P = 0.006) and for ERα + tamoxifen-
treated cases (BCR P = 0.004 Log Rank, HR 0.61 CI 0.43–
0.88 P = 0.009; BCS P = 0.009 Log Rank, HR 0.56 CI 0.34–
0.91 P = 0.020). The outcome benefit of concomitant high
ERβ2 mRNA and protein levels was particularly marked at
shorter follow-up, where this measure was the only inde-
pendent marker of improved outcome in the ERα +
tamoxifen-treated cohort using Cox multivariate analysis
including grade, size PgR status and nodal status (5-year
BCR HR 0.48 CI 0.24–0.95 P = 0.036, 7 year BCS HR 0.46
CI 0.23–0.92 P = 0.029). In the ERα + tamoxifen-treated,
node negative cases, having both high ERβ2 mRNA and
protein was significantly related to an improved BCS (P =
0.028 Log Rank).
Although ERβ2 protein levels are apparently not directly
related to mRNA levels, expression of ERβ2 protein may
be important because good outcome was observed for
those cases assessed as having both high mRNA and pro-
tein levels and this was independent in multivariate anal-
ysis. It is possible therefore that the relatively poor utility
of ERβ2 protein assessment by immunostaining as a
measure of outcome prediction may be due to high levels
of ERβ2 protein in some cases (with lower levels of ERβ2
mRNA) being related to some form of protein stabiliza-
tion, or detection of inactive ERβ2. The disparity between
protein and RNA expression for ERβ2 is even suggestive of
an inverse relationship. Nevertheless a significant propor-
tion of cancers (34%) had both high protein and high
mRNA levels and these had a significantly better outcome
than the remaining cases. This suggests that transcription
of ERβ2 mRNA drives ERβ2 protein levels in some cases,
and these cases do particularly well on tamoxifen treat-
ment. It is perhaps unsurprising that previous studies of
ERβ2 protein expression did not find significant associa-
tions between ERβ2 and outcome in ERα + tamoxifen
treated cases as these did not include measurement of
ERβ2 mRNA levels. They were thus unable to distinguish
between ERB2 protein associated with increased transcrip-
tion and that possibly present due to some form of post-
transcriptional control (or perhaps the breakdown of nor-
mal control).
Conclusion
Whilst our data would suggest that high ERβ2 levels could
contribute to an improved outcome in a subgroup of
patients, it provides further evidence that determination
of ERβ2 protein by immunostaining is unlikely to provide
the predictive test that is needed for better targeting of
additional therapy in those women for whom adjuvant
tamoxifen is not likely to be sufficient. The failure to link
protein expression to outcome measures does not pre-
clude the use of ERβ2 mRNA levels in a clinical setting.
Low ERβ2 mRNA was significantly associated with worse
outcomes in ERα + tamoxifen-treated patients independ-
ently of other factors such as grade and nodal status.
Larger trials to validate ERβ2 mRNA as a biomarker are
needed and should be extended to alternative adjuvant
endocrine therapies such as aromatase inhibitors.
List of abbreviations
BCR = breast cancer relapse; BCS = breast cancer survival;
CI = confidence interval; ERα = oestrogen receptor alpha;
ERβ = oestrogen receptor beta; HR = hazard ratio; MW =
Mann-Whitney U test; %+ = percentage positive cells; PgR
= progesterone receptor; qRTPCR = quantitative reverse-
transcription PCR analysis; ROC = Receiver Operating
Characteristic.
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